ECAT FOUNDATION

External quality Control for Assays and Tests

With a focus on Thrombosis and Haemostasis

REPORT



SURVEY 2023-H2 Haemophilia Labcode 1492

Copyright © 2023 ECAT Foundation



External quality Control for Assays and Tests With a focus on Thrombosis and Haemostasis

Version:

1.0.0

Survey: 2023-H2 Page 2 of 13 07-July-2023 Labcode: 1492

Date of Issue	:	07-July-2023	
Survey	:	2023-H2	
Report	:	Haemophilia	

Note:

In the Survey Manual 2023 detailed information is given regarding the ECAT external quality assessment programme, including the statistical evaluation and explanation of the report.

This Survey Manual 2023 should be considered as an integral part of this survey report.

Please notice the information regarding the homogeneity of samples used and the between-laboratory variation in the paragraph on the statistical evaluation of the Survey Manual.

General Information

Complaints

Any complaints regarding this survey report should be reported to the ECAT before **September 22nd, 2023**. Complaints received after this date will not be taken into consideration.

Multiple instruments

From 2019 you have the possibility to submit per parameter results for three different instruments and or methods. However, some participants have submitted three times the same results, suggesting that this are separate results. This is **not** the case and may affect the statistical analysis. We have excluded the results from the second and third test system in the statistical analysis. Do not submit multiple times the same results anymore in future surveys.

Exclusion of results

Results < [value] or > [value] are excluded in the statistical analysis.

When other results (e.g. deviating results) are excluded in the statistical analysis, these results are placed between brackets.

Participants in Factor VIII Inhibitor module

In the Factor VIII (FVIII) Inhibitor module a new parameter is introduced: Factor VIII Inhibitor (by type of test). The purpose is to discriminate between commercially available FVIII inhibitor tests (e.g. Precision Biologics, Technoclone) and lab-developed tests. A "Lab-developed test" is when you have set-up the inhibitor test in your own laboratory and not using a commercial available test. It is not the meaning to select Commercial Test because you use commercial reagents for the measurement of the residual FVIII. The option "Other" within the selection "Commercial Test" is most likely selected by a large group of participants because of the use of commercial reagents for FVIII determination. Please be aware to select the correct option, if not a commercial FVIII Inhibitor Test is used, the option "Lab-developed test" should be selected.

This report is authorized by:

Dr. M.J. van Essen-Hollestelle Programme Expert

<u>Note</u>: A printed version of the actual Survey Manual is provided to all participants once a year. This manual can also be downloaded from the member section of the ECAT website.

ECAT Foundation

Director: Dr. P. Meijer ECAT Office P.O. Box 107 2250 AC Voorschoten, The Netherlands phone +31 (0) 71 3030 910; fax + 31 (0) 71 3030 919 E-mail: info@ecat.nl Website: www.ecat.nl VAT number: NI 802836872B01

Registration number with the Chamber of Commerce (KvK) Gouda : 41174102 General terms of delivery are applicable to all our services.

All rights reserved. No part of this report may be reproduced, stored in a retrieval system, or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from the ECAT Foundation.



Survey: 2023-H2 Page 3 of 13 07-July-2023 Labcode: 1492

Version: 1.0.0

OVERVIEW Z-SCORES

UV:Satisfactory (-2 ≤ Z-score ≤ 2)

UV: Need at 3)

UV: Need attention (-3 < Z-score < -2 or 2 < Z-score <

UV:Unsatisfactory (Z-score \leq -3 or \geq 3) BV: Unacceptable

=)	3)				· onaccoptable			
								Bivarate
Module	Parameter	Sample	Test System	Total	Assay	Ν	lethod	Analysis
Factor VIII inhibitor	Factor VIII Inhibitor (by inhibitor assay conc	23.104	1	-1.54	-1.58		-1.92	
		23.105	1	-1.48	-1.49		-1.63	
Factor VIII inhibitor	Factor VIII Inhibitor (by FVIII assay)	23.104	1	-1.54	-1.26		-1.03	
		23.105	1	-1.48	-1.17		-1.14	
Factor VIII inhibitor	Factor VIII Inhibitor (Manufacturer)	23.104	1	-1.54	-1.54			
		23.105	1	-1.48	-1.47			



Survey: 2023-H2 Page 4 of 13 07-July-2023 Labcode: 1492

Factor VIII inhibitor

Factor VIII Inhibitor (by type of test)

Version:

1.0.0

Sample No	23.104							
Sample Details	Plasma with a Factor VIII In	hibitor level of approx. 11 BU/mL						
Prior Use	None							
Unit	BU/mL							
Expiry Date	31-December-2024							
Homogeneity	4.6 %	Homogeneity Parameter	FVIII inhibitor					
	For any method used for the measurement of this parameter with a CV ≤ 15.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details							
	the paragraph on the statistical evaluation in the Survey Manual.							
Number of Participants	352							
Number of Responders	326	Response Rate	93 %					
Comments	Participant 3828 submitted for three instruments the same results. The results of the second and third instrument were excluded in the statistical analysis.							
	The option "Other" within the selection "Commercial Test" is most likely selected by a large group of participants because of the use of commercial reagents for FVIII determination. Please be aware to select the correct option, if not a commercial FVIII Inhibitor Test is used, the option "Lab-developed test" should be selected.							


Your Classification

Positive

Own Reagent												
		n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
	Lab-developed test	225	8.3	0.18	25.6	0.9 - 35.2	5.0	-1.54				

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
Commercial Test	126	8.6	0.27	27.8	1.1 - 20.0
Other	67	8.5	0.45	34.3	1.1 - 20.0
Precision Biologics	22	8.5	0.45	19.9	3.3 - 16.8
Technoclone	37	8.7	0.41	23.0	5.1 - 13.4
Lab-developed test	225	8.3	0.18	25.6	0.9 - 35.2





Survey: 2023-H2 Page 5 of 13 07-July-2023 Labcode: 1492

Factor VIII inhibitor

Factor VIII Inhibitor (by type of test)

Version:

1.0.0


23.105							
Plasma with a Factor VIII Inhibitor leve	el of approx. 3.5 BU/mL						
None							
BU/mL							
31-December-2024							
6.8 %	Homogeneity Parameter	FVIII inhibitor					
For any method used for the measurement of this parameter with a $CV \le 22.7\%$ the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.							
352							
326	Response Rate	93 %					
Participant 3828 submitted for three instruments the same results. The results of the second and third instrument were excluded in the statistical analysis.							
The option "Other" within the selection "Commercial Test" is most likely selected by a large group of participants because of the use of commercial reagents for FVIII determination. Please be aware to select the correct option, if not a commercial FVIII Inhibitor Test is used, the option "Lab-developed test" should be selected.							
Positive							
	Plasma with a Factor VIII Inhibitor level None BU/mL 31-December-2024 6.8 % For any method used for the measure homogeneity could not be met and the the paragraph on the statistical evalua 352 326 Participant 3828 submitted for thre instrument were excluded in the statistical The option "Other" within the select participants because of the use of select the correct option, if not a con- test" should be selected.	Plasma with a Factor VIII Inhibitor level of approx. 3.5 BU/mL None BU/mL 31-December-2024 6.8 % Homogeneity Parameter For any method used for the measurement of this parameter with a C homogeneity could not be met and the Z-scores should be interpreted the paragraph on the statistical evaluation in the Survey Manual. 352 326 Response Rate Participant 3828 submitted for three instruments the same resu instrument were excluded in the statistical analysis. The option "Other" within the selection "Commercial Test" is mo participants because of the use of commercial reagents for FVII select the correct option, if not a commercial FVIII Inhibitor Test test" should be selected.					

-	_	
Own	Reag	ent

<u>Own Reagent</u>											
	n	assigned	Uncert.	CV (%)	Range	your	z-score	your	z-score	your	z-score
		value				result		result		result	
Lab-developed test	225	4.0	0.09	27.1	0.0 - 34.5	2.4	-1.47				

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
Commercial Test	126	4.0	0.12	27.2	0.9 - 9.7
Other	67	4.0	0.18	29.7	0.9 - 9.7
Precision Biologics	22	4.0	0.19	17.9	2.9 - 6.7
Technoclone	37	4.1	0.25	30.2	2.2 - 7.0
Lab-developed test	225	4.0	0.09	27.1	0.0 - 34.5



Т




External quality Control for Assays and Tests With a focus on Thrombosis and Haemostasis

1.0.0

Version:

Survey: 2023-H2 Page 6 of 13 07-July-2023 Labcode: 1492





Version:

Factor VIII inhibitor

Factor VIII Inhibitor (by inhibitor assay concept)

1.0.0

Sample No	23.104										
Sample Details	Plasma with a Factor VIII Inhibitor	level of approx. 11 BU/mL									
Prior Use	None										
Unit	BU/mL										
Expiry Date	31-December-2024										
Homogeneity	4.6 %	Homogeneity Parameter	FVIII inhibitor								
	For any method used for the mean	For any method used for the measurement of this parameter with a CV ≤ 15.3% the criterion for									
	homogeneity could not be met an	d the Z-scores should be interpreted	d with caution. See for further details								
	the paragraph on the statistical ev	valuation in the Survey Manual.									
Number of Participants	352										
Number of Responders	326	Response Rate	93 %								
Comments Participant 3828 submitted for three instruments the same results. The results of the second ar instrument were excluded in the statistical analysis.											

Your Classification


Positive


Own Reagent

	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
Buffered Normal Pooled Plasma	250	8.2	0.16	24.8	0.9 - 35.2	5.0	-1.58				
Buffer	94	8.7	0.25	22.1	4.2 - 32.0	5.0	-1.92				

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
Non-Buffered Normal Pooled Plasma	99	8.8	0.33	30.4	1.1 - 20.0
Buffer	54	9.2	0.46	29.1	2.9 - 20.0
Buffer + Albumin	2	10.4			9.9 - 10.9
Factor VIII Deficient Plasma	21	8.0	0.81	37.1	1.1 - 15.6
Heat-activated normal plasma	3	9.0			6.7 - 17.6
Other	11	8.6	0.77	24.0	6.2 - 14.0
Unknown	4	6.4			4.2 - 10.0
Buffered Normal Pooled Plasma	250	8.2	0.16	24.8	0.9 - 35.2
Buffer + Albumin	25	9.0	0.44	19.7	5.8 - 21.4
Factor VIII Deficient Plasma	97	7.6	0.26	27.1	0.9 - 14.0
Heat-inactivated normal plasma	17	7.6	0.50	21.8	0.9 - 11.8
Other	12	9.1	0.86	26.2	6.0 - 35.2
Unknown	1	13.7			-
Unknown	2	7.1			7.0 - 7.2
Buffer	1	7.2			-
Factor VIII Deficient Plasma	1	7.0			-





Buffer



Version:

Survey: 2023-H2 Page 8 of 13 07-July-2023 Labcode: 1492

Factor VIII inhibitor

Factor VIII Inhibitor (by inhibitor assay concept)

1.0.0

Sample No	23.105									
Sample Details	Plasma with a Factor VIII Inhibitor le	Plasma with a Factor VIII Inhibitor level of approx. 3.5 BU/mL								
Prior Use	None									
Unit	BU/mL									
Expiry Date	31-December-2024									
Homogeneity	6.8 %	Homogeneity Parameter	FVIII inhibitor							
	For any method used for the measu	rement of this parameter with a ${f C}$	$V \leq 22.7\%$ the criterion for							
	homogeneity could not be met and the	he Z-scores should be interpreted	with caution. See for further details							
	the paragraph on the statistical evalu	uation in the Survey Manual.								
Number of Participants	352									
Number of Responders	326	Response Rate	93 %							
Comments	1		Its. The results of the second and third							
	instrument were excluded in the	statistical analysis.								

Your Classification


Positive


Own Reagent

	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
Buffered Normal Pooled Plasma	250	3.9	0.08	26.4	0.0 - 34.5	2.4	-1.49				
Buffer	94	4.1	0.13	25.1	0.0 - 32.0	2.4	-1.63				

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
Non-Buffered Normal Pooled Plasma	99	4.2	0.15	28.2	0.9 - 11.1
Buffer	54	4.4	0.19	25.8	1.3 - 9.6
Buffer + Albumin	2	4.5			4.3 - 4.8
Factor VIII Deficient Plasma	21	3.8	0.39	37.7	0.9 - 11.1
Heat-activated normal plasma	3	5.4			3.3 - 5.6
Other	11	3.9	0.35	23.7	2.9 - 6.6
Unknown	4	2.8			1.4 - 5.0
Buffered Normal Pooled Plasma	250	3.9	0.08	26.4	0.0 - 34.5
Buffer + Albumin	25	4.4	0.33	29.8	2.9 - 10.5
Factor VIII Deficient Plasma	97	3.8	0.13	27.2	0.8 - 34.5
Heat-inactivated normal plasma	17	3.7	0.27	24.0	2.5 - 5.5
Other	12	4.1	0.39	26.6	2.5 - 5.6
Unknown	1	5.5			-
Unknown	2	2.9			2.6 - 3.2
Buffer	1	3.2			-
Factor VIII Deficient Plasma	1	2.6			-





Buffer



Factor VIII inhibitor

N

Ņ

4

2

Ņ

4


Z-score sample 2 0

Z-score sample 2 0

1.0.0 Version:


Factor VIII Inhibitor (by inhibitor assay concept)


Instrument ID Bivariate Z-score plots (by survey) Z-score history (by survey) Z-score history (by consensus value) Z-score Z-score -4 -2 0 2 4 ż 3 4 5 6 2023-H2 0 Z-score sample 1 Instrument ID Bivariate Z-score plots (by survey) Z-score history (by survey) attentio Z-score Z-score -2 2 -4 0 4 ź 3 5 6 2023-H2 ō 4 7 Z-score sample 1 Instrument ID Bivariate Z-score plots (by survey) Z-score history (by survey) Z-score history (by consensus value)




Z-score history (by consensus value)

8









Survey: 2023-H2 Page 10 of 13 07-July-2023 Labcode: 1492

Factor VIII inhibitor

Factor VIII Inhibitor (by FVIII assay)

1.0.0

Version:

Sample No	23.104							
Sample Details	Plasma with a Factor VIII Inh	ibitor level of approx. 11 BU/mL						
Prior Use	None							
Unit	BU/mL							
Expiry Date	31-December-2024							
Homogeneity	4.6 %	Homogeneity Parameter	FVIII inhibitor					
	For any method used for the measurement of this parameter with a CV \leq 15.3% the criterion for							
	homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details							
	the paragraph on the statistical evaluation in the Survey Manual.							
Number of Participants	352							
Number of Responders	326	Response Rate	93 %					
Comments	Participant 3828 submitter instrument were excluded		Its. The results of the second and third					

Your Classification


on


Positive

Own Reagent											
	n	assigned	Uncert.	CV (%)	Range	your	z-score	your	z-score	your	z-score
		value				result		result		result	
Chromogenic assay	49	7.5	0.36	26.6	0.9 - 17.2	5.0	-1.26				
Siemens Factor VIII	18	7.3	0.67	30.9	4.2 - 13.7	5.0	-1.03				

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
One-stage clotting assay	302	8.5	0.16	25.5	0.9 - 35.2
Hemoliance Synthasil APTT	1	17.9			-
Hyphen Biomed Cephen	1	13.5			-
IL HemosIL APTT lyophilised silica	3	8.2			7.3 - 12.4
IL HemosIL APTT-SP liquid silica	5	7.6			5.6 - 8.1
IL HemosIL SynthASil	100	8.9	0.32	28.9	3.2 - 35.2
Other	1	4.7			-
Roche APTT	2	8.4			7.7 - 9.0
Siemens Actin FS	46	7.9	0.33	22.8	3.5 - 14.0
Siemens Actin FSL	10	8.5	0.29	8.5	6.4 - 14.0
Siemens Pathromtin SL	40	9.1	0.53	29.8	1.1 - 20.0
Stago Cephalin/Kaolin/CK Prest	43	8.5	0.29	18.2	3.1 - 10.7
Stago Cephascreen	2	7.7			5.4 - 10.0
Stago PTT (automate)	12	9.4	1.01	30.0	1.1 - 12.9
Tcoag Automated APTT	1	9.0			-
Tcoag TriniClot APTT S	2	4.2			2.9 - 5.5
Tcoag TriniClot APTT-HS	3	8.0			6.5 - 8.9
Technoclone Dapttin	1	8.6			-
Technoclone Siron LS	1	8.5			-
Chromogenic assay	49	7.5	0.36	26.6	0.9 - 17.2
Chromogenix Coamatic Factor VIII	11	6.9	0.57	21.8	0.9 - 9.4
Chromogenix Coatest SP Factor VIII	3	6.0			6.0 - 6.1
Hyphen Biomed Biophen Factor VIII	1	16.8			-
IL Electrachrome FVIII	2	12.9			8.6 - 17.2
Other	2	7.0			7.0 - 7.1
Precision Biologic Cryocheck Chromog	5	8.0			3.3 - 9.1
TCoag Trinichrom FVIII	1	11.5			-
Technoclone Factor VIII	3	8.5			7.3 - 8.9





Siemens



Survey: 2023-H2 Page 11 of 13 07-July-2023 Labcode: 1492

Factor VIII inhibitor

Factor VIII Inhibitor (by FVIII assay)

1.0.0

Version:

Sample No	23.105								
Sample Details	Plasma with a Factor VIII Inhibitor level of approx. 3.5 BU/mL								
Prior Use	None								
Unit	BU/mL								
Expiry Date	31-December-2024								
Homogeneity	6.8 %	Homogeneity Parameter	FVIII inhibitor						
	For any method used for the measu	rement of this parameter with a C	$V \leq 22.7\%$ the criterion for						
	homogeneity could not be met and	the Z-scores should be interpreted	with caution. See for further details						
	the paragraph on the statistical eval	uation in the Survey Manual.							
Number of Participants	352								
Number of Responders	326	Response Rate	93 %						
Comments	Participant 3828 submitted for three instruments the same results. The results of the second and third instrument were excluded in the statistical analysis.								

Your Classification


Positive


Own Reagent

	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
Chromogenic assay	49	3.5	0.17	27.1	2.1 - 9.6	2.4	-1.17				
Siemens Factor VIII	18	3.8	0.35	31.6	2.4 - 8.0	2.4	-1.14				

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
One-stage clotting assay	302	4.1	0.08	26.2	0.0 - 34.5
Hemoliance Synthasil APTT	1	9.7			-
Hyphen Biomed Cephen	1	4.3			-
IL HemosIL APTT lyophilised silica	3	3.5			3.3 - 4.8
IL HemosIL APTT-SP liquid silica	5	3.3			2.8 - 4.5
IL HemosIL SynthASil	100	4.3	0.16	29.7	2.0 - 10.5
Other	1	4.4			-
Roche APTT	2	3.7			3.0 - 4.4
Siemens Actin FS	46	3.8	0.17	24.1	2.4 - 34.5
Siemens Actin FSL	10	4.5	0.26	14.8	3.3 - 5.4
Siemens Pathromtin SL	40	4.3	0.23	27.9	0.9 - 6.1
Stago Cephalin/Kaolin/CK Prest	43	4.0	0.14	18.3	2.2 - 7.0
Stago Cephascreen	2	3.8			2.9 - 4.7
Stago PTT (automate)	12	4.4	0.27	16.9	0.9 - 5.4
Tcoag Automated APTT	1	4.0			-
Tcoag TriniClot APTT S	2	2.0			1.3 - 2.7
Tcoag TriniClot APTT-HS	3	4.0			3.1 - 4.9
Technoclone Dapttin	1	3.9			-
Technoclone Siron LS	1	3.7			-
Chromogenic assay	49	3.5	0.17	27.1	2.1 - 9.6
Chromogenix Coamatic Factor VIII	11	3.0	0.25	21.7	2.1 - 4.4
Chromogenix Coatest SP Factor VIII	3	2.9			2.6 - 2.9
Hyphen Biomed Biophen Factor VIII	1	6.7			-
IL Electrachrome FVIII	2	6.5			3.5 - 9.6
Other	2	2.8			2.5 - 3.0
Precision Biologic Cryocheck Chromog	5	3.2			3.0 - 4.6
TCoag Trinichrom FVIII	1	4.3			-
Technoclone Factor VIII	3	3.7			3.5 - 4.3





Siemens




External quality Control for Assays and Tests With a focus on Thrombosis and Haemostasis

1.0.0

Version:

Survey: 2023-H2 Page 12 of 13 07-July-2023 Labcode: 1492





Survey: 2023-H2 Page 13 of 13 07-July-2023 Labcode: 1492

1.0.0 Version: